Market Performance - The A-share market saw all three major indices rise, with the Shanghai Composite Index up by 1.38%, the Shenzhen Component Index up by 2.24%, and the ChiNext Index up by 2.85% [1] - The total market turnover reached 2.57 trillion yuan, showing an increase compared to the pre-holiday period [1] Driving Factors for the Rise - The significant rise in the Hong Kong stock market during the New Year period catalyzed the positive opening of the A-share market [3] - Key drivers include: - Intensified global AI application [3] - Increased interest in innovative pharmaceuticals [3] - Strengthening of the Renminbi, with the offshore Renminbi breaking the 7 mark, enhancing the attractiveness of Hong Kong stocks to foreign capital [3] Future Outlook - Externally, the imminent announcement of the new Federal Reserve chairperson and ongoing pressure from Trump for significant interest rate cuts may reinforce expectations for a weaker dollar [4] - Internally, various policies are being implemented to stabilize expectations and stimulate activity, such as optimizing housing purchase restrictions and reducing the value-added tax on second-hand housing [4] - The Guotai CSI 500 ETF (561350) tracks the CSI 500 Index, which focuses on emerging manufacturing and growth sectors like electronics and biomedicine, reflecting China's economic transformation [4] - The Hong Kong Stock Connect 50 ETF (159712) tracks the Hong Kong Stock Connect 50 Index, which includes large-cap blue-chip stocks across various sectors, providing good market representation and industry distribution [4] Industry Developments - Meta has acquired Manus for over $2 billion to enhance its AI agent capabilities [6] - Volcano Engine will be the exclusive AI cloud partner for the 2026 Spring Festival Gala [6] - Deepseek has released a new architecture paper that balances model training performance and efficiency [6] - The brain-computer interface sector is gaining traction, with Elon Musk's Neuralink set to begin large-scale production of brain-computer interface devices in 2026 [6] - The first industry standard for medical devices using brain-computer interface technology will be implemented on January 1, 2026, laying the foundation for standardized development in the industry [6] - The small nucleic acid drug sector is heating up, with Rebio Biotechnology set to enter the Hong Kong market, further stimulating market sentiment [6]

Group 1 - The core viewpoint of the article highlights the significant rise of the Guotai Science and Technology Artificial Intelligence ETF (589110), which increased by over 2.4%, driven by the focus on semiconductor localization and 3D printing applications [1] - According to Fangzheng Securities, the "14th Five-Year Plan" accelerates the self-sufficiency of semiconductors, indicating a rapid development period for the entire advanced manufacturing industry chain [1] - There is a notable gap between domestic storage capacity and global leaders, necessitating sufficient capacity to ensure a stable supply system [1] Group 2 - Domestic semiconductors are expected to improve their localization rate as they undergo multiple rounds of joint research, validation testing, and small-scale production, particularly as end customers expand their production [1] - The Guotai Science and Technology Artificial Intelligence ETF tracks the Science and Technology AI Index (950180), which has a daily price fluctuation limit of 20% and selects 30 large-cap AI-related listed companies from the Sci-Tech Innovation Board [1] - The index has a high concentration and a clear theme, focusing on hard technology fields such as semiconductors, making it suitable as an aggressive investment tool [1]

Group 1 - The core viewpoint of the article highlights the significant inflow of over 4.4 billion yuan into the Science and Technology Innovation Bond ETF (551880) in the past 10 days, indicating a growing interest in investment opportunities within this sector [1] - The introduction of the Science and Technology Innovation Bond ETF provides investors with a new tool to share in the benefits of science and technology policies while maintaining relatively stable returns [1] - The rapid development of credit bond ETFs this year, with direct regulatory support for the Science and Technology Innovation Bond ETF, emphasizes its importance as a sub-sector [1] Group 2 - The Science and Technology Innovation Bond ETF allows for "same-day subscription and redemption" and "T+0" trading, addressing the liquidity issues often faced in the credit bond market [1] - This ETF lowers the investment threshold for bonds, making it easier for small and micro institutions as well as individual investors to participate in the science and technology bond market [1] - The ETF offers a convenient way to access a basket of high-grade science and technology bonds, reducing research costs and solving the challenges of diversified investment [1] Group 3 - The unique investment value of the Science and Technology Innovation Bond ETF lies in its ability to withstand short-term fluctuations in the bond market due to its high-grade credit bond foundation [1] - It also allows investors to benefit from the long-term development opportunities in the technology innovation sector, supported by ongoing policy incentives [1] - This ETF is positioned as a quality allocation choice that balances risk and return for investors [1]

1月5日，创业板人工智能ETF国泰（159388）涨超0.9%，通信行业韧性修复引关注 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 创业板人工智能ETF国泰（159388）跟踪的是创业板人工智能指数（970070），该指数从创业板市 场中选取涉及人工智能技术研发、智能系统集成等业务的上市公司证券作为指数样本，以反映人工智能 领域高成长创新企业的整体表现。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构 成投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产 品要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 每日经济新闻 国信证券指出，通信行业在生命周期两个阶段均展现出全方位领先优势。在 ...

Group 1 - The core viewpoint highlights the continuous catalysis in the innovative drug sector, particularly with the announcement from Elon Musk that Neuralink will start large-scale production of brain-machine interface devices in 2026, transitioning to fully automated surgical processes [1] - The first national standard for brain-machine interface medical devices in China will be implemented on January 1, 2026, laying the foundation for the standardized development of the industry [1] - The market sentiment is further catalyzed by the upcoming listing of Rebio Biotech on the Hong Kong stock market, enhancing the interest in small nucleic acid drugs that regulate pathological processes at the genetic level [1] Group 2 - Zai Lab has reached a strategic cooperation with AbbVie regarding ZG006, with an upfront payment of $100 million and a total transaction value potentially reaching $1.075 billion plus sales sharing, indicating the global value recognition of the product by multinational corporations [1] - According to Founder Securities, core assets in innovative drugs are expected to continue rising, with new opportunities emerging in small nucleic acids and in vivo CAR technologies, reflecting a long-term industry trend [1] - The innovative drug business development is seen as a value realization for China's innovative drug capabilities on the global stage, with authorized core assets expected to continue realizing value as clinical progress advances [1] Group 3 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech [2] - During the market rebound period from September 24, 2024, to October 31, 2025, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index recorded gains of 143.70% and 135.34% respectively, suggesting that the Sci-Tech Innovation Drug Index may help share the resilience of the Sci-Tech Innovation Board when market risk appetite increases [2]

Group 1 - The pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global layout, with a resonance of industrial, policy, and capital cycles expected by 2026, leading to a potential performance inflection point and valuation reshaping for Chinese innovative drugs, particularly in next-generation therapies such as ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - The impact of policies on the medical device industry is diminishing, with over half of the market covered by centralized procurement, allowing domestic companies to achieve technological breakthroughs in certain high-end fields and surpass foreign competitors, alongside rapid growth in exports, which are expected to increase by 7.3% year-on-year from January to November 2025 [1] - The medical equipment sector is driven by a significant increase in procurement volume, with a projected 40% year-on-year growth in bidding amounts for 2025, positioning flow-type products and high-end export enterprises for high growth [1] - The demand for blood products and plasma collection continues to grow, with resources concentrating towards leading companies, and stable demand for major products such as albumin and immunoglobulin [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovative Medicine Index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies in the biotechnology, genetic engineering, and new drug development sectors from the ChiNext market to reflect the overall performance of high-growth and innovative biopharmaceutical frontier enterprises [1]

Group 1 - The core viewpoint is that the ChiNext 50 index, representing the technology growth sector, achieved a notable increase of 4.93% in December, indicating strong performance in the year-end market [1] - The main focus of the industry revolves around semiconductors, AI, and future industry hotspots, with government support for new smart glasses and smart home initiatives, as well as the launch of the National Venture Capital Guidance Fund targeting early-stage projects in integrated circuits and artificial intelligence [1] - The global technology stocks are experiencing a synchronized upward trend, with semiconductors and AI chips being the core of the market rally, driven by domestic policy support and valuation recovery in the technology sector [1] Group 2 - The ChiNext 50 ETF (159375) tracks the ChiNext 50 index (399673), which has a daily price fluctuation limit of 20%, and is composed of 50 stocks with high average trading volumes and good liquidity from the ChiNext market [1] - The constituent stocks of the ChiNext 50 index are primarily distributed across high-tech sectors such as power equipment and new energy, pharmaceuticals, and information technology, showcasing significant growth characteristics [1] - The medium to long-term outlook is positive for industrial metals and minor metals, with an upward price trend driven by global liquidity easing and emerging demands from AI and new energy sectors [1]

Group 1 - The core viewpoint emphasizes the expectation of a spring market rally in 2026, driven by policy dividends and structural opportunities in line with the "14th Five-Year Plan" [1] - The China Securities A500 ETF (159338) has seen a net inflow of nearly 15 billion yuan over the past 20 days, indicating strong investor interest [1] - The A500 index, which the ETF tracks, selects samples from leading companies across various industries, reflecting a balanced representation of market capitalization and industry distribution [1] Group 2 - Compared to the CSI 300, the A500 index emphasizes industry balance and leading companies, providing a better beta base during industrial upgrades [2] - As of December 30, 2025, the A500 index has increased by 465.87% since its base date, outperforming the CSI 300 index, which rose by 363.28%, resulting in an excess return of 102.59% [2] - The number of accounts for the Guotai CSI A500 ETF is three times that of its closest competitor, indicating a strong preference among investors for this ETF [2]

Core Viewpoint - The bond ETF market, particularly the Sci-Tech bond ETFs, has experienced rapid growth, reaching a scale of nearly 350 billion yuan within just six months, indicating a significant shift in investor interest towards bond ETFs as compared to stock ETFs [1][6]. Group 1: Market Growth - As of December 30, 2025, the total scale of bond ETFs reached 813.26 billion yuan, representing a growth of over 360% since the beginning of the year [4]. - The rapid influx of funds into Sci-Tech bond ETFs has driven the overall credit bond ETF scale close to 600 billion yuan [5][6]. - The first batch of 10 Sci-Tech bond ETFs launched in July 2025 sold out on the first day, showcasing high market demand [7]. Group 2: Factors Driving Popularity - The growth of Sci-Tech bond ETFs is attributed to several factors, including supportive policies, product advantages, and the attractiveness of underlying assets [9]. - The introduction of the "Technology Board" policy in May 2025 laid the groundwork for the launch of Sci-Tech bond ETFs [10]. - The product features such as T+0 trading, pledge repurchase capability, low fees, and high transparency align well with institutional investors' needs [11]. Group 3: Underlying Assets - Sci-Tech bond ETFs primarily invest in credit bonds issued by technology innovation institutions or those focused on technology innovation, with a majority being AAA-rated bonds from state-owned enterprises [13]. - The AAA Sci-Tech bond index tracked by the Jia Shi Sci-Tech bond ETF has shown an annualized return of 4.11% since its base date, with a low annualized volatility of 1.02%, outperforming many short and medium-term bond funds [13]. Group 4: Target Investors - Sci-Tech bond ETFs are suitable for specific types of investors, particularly institutional investors looking to optimize asset allocation [15][16]. - Long-term funds such as pensions, insurance, and bank wealth management products are using these ETFs as core underlying assets for asset-liability matching and liquidity management [17]. - For individual investors seeking stability, Sci-Tech bond ETFs offer a less volatile investment option compared to direct stock market investments, along with regular coupon income [18].

风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构 成投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产 品要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 每日经济新闻 华龙证券指出，通信行业2025年前三季度业绩稳中有升，盈利能力小幅提升，光通信子行业表现亮 眼，营业收入同比增长34.94%，归母净利润同比增长128.35%。光模块需求持续高增，受益于AI基础设 施建设对以太网交换机和高速光模块的强劲需求，以及光互连技术在AI scale-up网络中的应用推广，市 场规模有望持续快速增长。中国厂商在全球光模块领域占据主导地位，2024年TOP10榜单中占7席，高 速光模块需求提升有望带动行业盈利能力提升。卫星互联网加速发展，2025年政府工作报告强调商业航 天技术突破与规模化应用，中国低轨卫星互联网建设加速推进，2026年国内低轨通信卫星发射量有望爆 发式增长。预计到2030年低轨卫星市场规模有望突破千亿甚至1500 ...